The choroidal macular neovascularisation (NVC) of the young subject is a serious condition that threatens visual function. The decrease in marked visual acuity is related to the foveolar or juxta-foveolar localization of the neovessels. The therapeutic management of idiopathic NVC of the young subject is difficult due to frequent recurrences despite the treatment. The use of anti-VEGF (vascular endothelial growth factor) represented a turning point in the management of this condition. The intravitreal (IVT) injection of bevacizumab appears to be effective and well tolerated.